Ser19

Site Information
APRRRsPsPtPtPGP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 478530

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ) , mutation of modification site ( 2 , 13 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:	breast cancer ( 7 , 8 , 17 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 7 ) , colorectal cancer ( 2 , 13 ) , colorectal carcinoma ( 2 , 13 ) , leukemia ( 20 ) , acute myelogenous leukemia ( 20 ) , lung cancer ( 12 , 17 , 22 , 28 ) , non-small cell lung cancer ( 17 , 28 ) , non-small cell lung adenocarcinoma ( 12 ) , ovarian cancer ( 7 ) , pancreatic ductal adenocarcinoma ( 11 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 11 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 24 ) , 293 (epithelial) [AT1 (human), transfection] ( 23 ) , 786-O (renal) [VHL (human), transfection] ( 5 ) , 786-O (renal) ( 5 ) , breast ( 4 , 7 ) , CL1-0 (pulmonary) ( 22 ) , CL1-1 (pulmonary) ( 22 ) , CL1-2 (pulmonary) ( 22 ) , CL1-5 (pulmonary) ( 22 ) , DLD1 (intestinal) ( 2 ) , fibroblast-skin ( 34 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , GM00130 (B lymphocyte) ( 26 ) , H2009 (pulmonary) ( 17 ) , H2077 (pulmonary) ( 17 ) , H2887 (pulmonary) ( 17 ) , H322M (pulmonary) ( 17 ) , HCC1359 (pulmonary) ( 17 ) , HCC1937 (breast cell) ( 17 ) , HCC366 (pulmonary) ( 17 ) , HCC4006 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 17 ) , HCT116 (intestinal) ( 13 ) , HeLa (cervical) ( 3 , 16 , 29 ) , HeLa_Meta (cervical) ( 25 ) , HeLa_Pro (cervical) ( 25 ) , HeLa_Telo (cervical) ( 25 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HOP62 (pulmonary) ( 17 ) , HUES-9 ('stem, embryonic') ( 21 ) , Jurkat (T lymphocyte) ( 14 , 31 , 32 , 33 ) , K562 (erythroid) ( 16 , 27 , 30 ) , KG-1 (myeloid) ( 20 ) , liver ( 10 ) , lung ( 12 ) , MCF-7 (breast cell) ( 17 ) , MCF10A1 (epithelial) ( 2 ) , NCI-H1299 (pulmonary) ( 28 ) , NCI-H1395 (pulmonary) ( 17 ) , NCI-H157 (pulmonary) ( 17 ) , NCI-H1666 (pulmonary) ( 17 ) , NCI-H2030 (pulmonary) ( 17 ) , NCI-H322 (pulmonary) ( 17 ) , NCI-H520 (squamous) ( 17 ) , ovary ( 7 ) , PC9 (pulmonary) ( 17 ) , SH-SY5Y (neural crest) ( 9 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Putative in vivo kinases:	CDK2 (human) ( 2 )
Kinases, in vitro:	CDK2 (human) ( 2 )
Treatments:	dasatinib ( 27 ) , LRRK2-IN-1 ( 9 ) , metastatic potential ( 22 )

Downstream Regulation
Effects of modification on CENPA:	intracellular localization ( 2 ) , molecular association, regulation ( 2 ) , protein conformation ( 13 )
Effects of modification on biological processes:	cell cycle regulation ( 2 , 13 ) , cell growth, induced ( 2 )
Inhibit interaction with:	HJURP (human) ( 2 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Takada M, et al. (2017) FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A. Cancer Res 77, 4881-4893 28760857 Curated Info
3	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
4	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
5	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
6	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
10	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
11	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
12	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
13	Bailey AO, et al. (2013) Posttranslational modification of CENP-A influences the conformation of centromeric chromatin. Proc Natl Acad Sci U S A 110, 11827-32 23818633 Curated Info
14	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
15	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
16	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
17	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
18	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
19	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
20	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
21	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
22	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
23	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
24	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
25	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
26	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
27	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
28	Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69 18707149 Curated Info
29	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
30	Stokes M (2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
31	Stokes M (2008) CST Curation Set: 3881; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
32	Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
33	Possemato A (2008) CST Curation Set: 3770; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
34	Yang F, et al. (2006) Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res 5, 1252-60 16674116 Curated Info